22 successful consortia are funded under the 2021 ERA PerMed call, with a total investment of approximately 27 million Euros for three years. The topics of the excellent projects that were selected for funding include a broad range of different diseases, such as cancer, renal diseases, cardiovascular diseases, chronic obstructive pulmonary diseases, neurological diseases, rheumatoid arthritis and systemic auto-inflammatory diseases.
The newsletter presents the topics, objectives and researchers involved in the successful consortia and is available here.
ERA PerMed is an ERA-Net Cofund, supported by 32 partners of 23 countries and co-funded by the European Commission.
Please note: The current ERA PerMed Joint Transnational Call “Prevention in Personalised Medicine” is still open for applications until February 17, 2022. More information is available here.